OS Therapies Incorporated (OSTX) - Total Assets
Based on the latest financial reports, OS Therapies Incorporated (OSTX) holds total assets worth $8.95 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See OSTX net asset value for net asset value and shareholders' equity analysis.
OS Therapies Incorporated - Total Assets Trend (2020–2024)
This chart illustrates how OS Therapies Incorporated's total assets have evolved over time, based on quarterly financial data.
OS Therapies Incorporated - Asset Composition Analysis
Current Asset Composition (December 2024)
OS Therapies Incorporated's total assets of $8.95 Million consist of 99.9% current assets and 0.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 99.9% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2020–2024)
This chart illustrates how OS Therapies Incorporated's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see OS Therapies Incorporated (OSTX) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: OS Therapies Incorporated's current assets represent 99.9% of total assets in 2024, an increase from 99.9% in 2020.
- Cash Position: Cash and equivalents constituted 99.9% of total assets in 2024, up from 73.5% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2020.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
OS Therapies Incorporated Competitors by Total Assets
Key competitors of OS Therapies Incorporated based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Sagimet Biosciences Inc. Series A Common Stock
NASDAQ:SGMT
|
USA | $107.75 Million |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
|
USA | $1.53 Billion |
|
Inner Mongolia Furui Med Sci
SHE:300049
|
China | CN¥3.42 Billion |
|
Bio-Thera Solutions Ltd
SHG:688177
|
China | CN¥2.39 Billion |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
|
Gubra A/S
CO:GUBRA
|
Denmark | Dkr1.32 Billion |
OS Therapies Incorporated - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.56 | 0.76 | 0.09 |
| Quick Ratio | 0.56 | 0.76 | 0.09 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-1.82 Million | $-613.79K | $-3.18 Million |
OS Therapies Incorporated - Advanced Valuation Insights
This section examines the relationship between OS Therapies Incorporated's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 11.81 |
| Latest Market Cap to Assets Ratio | 7.76 |
| Asset Growth Rate (YoY) | 594.0% |
| Total Assets | $5.54 Million |
| Market Capitalization | $42.96 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values OS Therapies Incorporated's assets at a significant premium (7.76x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: OS Therapies Incorporated's assets grew by 594.0% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for OS Therapies Incorporated (2020–2024)
The table below shows the annual total assets of OS Therapies Incorporated from 2020 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $5.54 Million | +594.01% |
| 2023-12-31 | $798.08K | +56.76% |
| 2022-12-31 | $509.11K | +56.22% |
| 2021-12-31 | $325.89K | -99.98% |
| 2020-12-31 | $1.68 Billion | -- |
About OS Therapies Incorporated
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide lin… Read more